CL2021002051A1 - Administración del virus adenoasociado de polinucleótido de cln6. - Google Patents

Administración del virus adenoasociado de polinucleótido de cln6.

Info

Publication number
CL2021002051A1
CL2021002051A1 CL2021002051A CL2021002051A CL2021002051A1 CL 2021002051 A1 CL2021002051 A1 CL 2021002051A1 CL 2021002051 A CL2021002051 A CL 2021002051A CL 2021002051 A CL2021002051 A CL 2021002051A CL 2021002051 A1 CL2021002051 A1 CL 2021002051A1
Authority
CL
Chile
Prior art keywords
cln6
polynucleotide
administration
associated virus
adeno
Prior art date
Application number
CL2021002051A
Other languages
English (en)
Inventor
Kathrin Meyer
Brian K Kaspar
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of CL2021002051A1 publication Critical patent/CL2021002051A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a la administración del virus adenoasociado recombinante (rAAV) de un polinucleótido de lipofuscinosis ceroide neuronal 6 (CLN6). La divulgación proporciona el rAAV y métodos para utilizar el rAAV en el tratamiento génico de CLN6 de la lipofuscinosis ceroide neuronal o la enfermedad de Batten CLN6.
CL2021002051A 2019-02-04 2021-08-03 Administración del virus adenoasociado de polinucleótido de cln6. CL2021002051A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962800915P 2019-02-04 2019-02-04
US201962880641P 2019-07-30 2019-07-30
US201962881151P 2019-07-31 2019-07-31
US201962912977P 2019-10-09 2019-10-09
US201962923125P 2019-10-18 2019-10-18

Publications (1)

Publication Number Publication Date
CL2021002051A1 true CL2021002051A1 (es) 2022-04-08

Family

ID=69771088

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002051A CL2021002051A1 (es) 2019-02-04 2021-08-03 Administración del virus adenoasociado de polinucleótido de cln6.

Country Status (14)

Country Link
US (1) US20220202956A1 (es)
EP (1) EP3921429A1 (es)
JP (1) JP2022519597A (es)
KR (1) KR20210124299A (es)
CN (1) CN113574176A (es)
AU (1) AU2020218501A1 (es)
BR (1) BR112021015150A2 (es)
CA (1) CA3127801A1 (es)
CL (1) CL2021002051A1 (es)
IL (1) IL285329A (es)
MX (1) MX2021009404A (es)
SG (1) SG11202107983TA (es)
TW (1) TW202033768A (es)
WO (1) WO2020163299A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2879719T3 (en) 2012-08-01 2018-09-03 Nationwide Childrens Hospital INTRATEKAL ADMINISTRATION OF RECOMBINANT ADENOASSOCATED VIRUSES
WO2023018674A1 (en) * 2021-08-09 2023-02-16 Amicus Therapeutics, Inc. Determination of gene transduction potency in neuron-like cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE272123T1 (de) 1993-11-09 2004-08-15 Ohio Med College Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
JPH10511264A (ja) 1994-12-06 1998-11-04 ターゲティッド ジェネティックス コーポレイション 高力価組換えａａｖベクターの生成のためのパッケージング細胞株
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
CA2230655C (en) 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
EP0850313B8 (en) 1995-09-08 2009-07-29 Genzyme Corporation Improved aav vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
IL128779A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania Method for recombinant adeno-associated virus-directed gene therapy
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2013078316A1 (en) 2011-11-23 2013-05-30 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
JP6202701B2 (ja) 2014-03-21 2017-09-27 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及びプログラム
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
CA2967468A1 (en) * 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
US11826433B2 (en) * 2016-02-02 2023-11-28 University Of Massachusetts Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
HUE064408T2 (hu) * 2016-02-05 2024-03-28 Univ Emory Egyszálú vagy önkomplementer adeno-asszociált vírus 9 injekciója cerebrospinális folyadékba

Also Published As

Publication number Publication date
CA3127801A1 (en) 2020-08-13
MX2021009404A (es) 2021-11-12
SG11202107983TA (en) 2021-08-30
JP2022519597A (ja) 2022-03-24
TW202033768A (zh) 2020-09-16
US20220202956A1 (en) 2022-06-30
WO2020163299A1 (en) 2020-08-13
EP3921429A1 (en) 2021-12-15
IL285329A (en) 2021-09-30
KR20210124299A (ko) 2021-10-14
AU2020218501A1 (en) 2021-08-19
BR112021015150A2 (pt) 2021-09-28
CN113574176A (zh) 2021-10-29

Similar Documents

Publication Publication Date Title
CL2021002049A1 (es) Administración de virus adenoasociado de polinucleótido de cln3.
CL2021002051A1 (es) Administración del virus adenoasociado de polinucleótido de cln6.
MX2017014204A (es) Formulaciones de tpp1 y metodos para tratar la enfemedad de cln2.
BR112022008641A2 (pt) Métodos de tratamento com modulador de miosina
EA201791199A1 (ru) Способ лечения болезни альцгеймера
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
MX2019007873A (es) Terapia génica para tratar la enfermedad de wilson.
CO2020006148A2 (es) Métodos y materiales para terapia génica con nt-3
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
CU20160088A7 (es) Piperidinil-tetrahidroquinolinas sustituidas
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
CR20160277A (es) Piperidinil tetrahidroquinolinas sustituidas
BR112016017478A2 (pt) novos tratamentos
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
BR112018017247A2 (pt) ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença?
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
PE20201166A1 (es) Metodos y composiciones para tratar enfermedades pulmonares cronicas
CL2021003337A1 (es) Tratamiento de la insuficiencia cardíaca en individuos humanos.
CL2022001177A1 (es) Tregímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax.
AR124827A1 (es) Suministro por virus adeno-asociado de polinucleótido cln3
CO2020014399A2 (es) Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
PE20181329A1 (es) Metodos y composiciones para el tratamiento del sindrome de hunter